Literature DB >> 11032698

Vascular endothelial growth factor release following coronary artery bypass surgery: extracorporeal circulation versus 'beating heart' surgery.

P B Burton1, V J Owen, S Hafizi, P J Barton, G Carr-White, T Koh, A De Souza, M H Yacoub, J R Pepper.   

Abstract

AIMS: The aim of this study was to examine the circulating levels of vascular endothelial growth factor, following coronary artery bypass graft surgery performed using both standard cardiopulmonary bypass or the 'octopus technique' on the beating heart.
BACKGROUND: Vascular endothelial growth factor has a number of effects that are beneficial in the setting of coronary artery bypass graft surgery including cardioprotection, potent angiogenic activity and amelioration of intimal hyperplasia. Hypoxia is a powerful stimulator of vascular endothelial growth factor expression yet the ability of ischaemia, occurring during coronary artery bypass graft surgery, to induce vascular endothelial growth factor production is unknown. METHODS AND
RESULTS: Serum vascular endothelial growth factor levels were determined in patients undergoing coronary artery bypass graft surgery with standard cardiopulmonary bypass (CPB-CABG group; n=20), with off-pump coronary artery bypass; (OP-CABG; n=12) and in patients undergoing non-cardiac major surgery (n=6). The effect of hypoxia on vascular endothelial growth factor release by neonatal rat cardiac myocytes in vitro was studied. In the CPB-CABG group vascular endothelial growth factor levels were significantly increased to 78.5+/-39.3 and 110.5+/-16.3 pg. microl(-1)8 and 24 h post-operatively, declining to 14.9+/-9.9 pg. microl(-1)by 48 h to pre-operative values (14.4+/-8.6 pg. microl(-1)). Significantly higher vascular endothelial growth factor levels were also present in the OP-CABG group 3, 6 and 24 h post-operatively (levels 136. 6+/-29.3, 143+/-26.12 pg. microl(-1)and 93.5+/-20.1 pg. microl(-1), respectively). However, non-cardiac major surgery did not result in elevated vascular endothelial growth factor levels post-operatively (46.36+/-9.76 vs pre-surgery levels of 26.84+/-6.1 pg. microl(-1)). Either 15 min or 3 h of hypoxia stimulated vascular endothelial growth factor release from neonatal rat cardiac myocytes in vitro. Twenty-four and 48 h post hypoxia, levels of vascular endothelial growth factor were significantly elevated by approximately 17.5- and 48.5-fold respectively.
CONCLUSIONS: These data demonstrate myocardial ischaemia secondary to CPB-CABG and OP-CABG to be a potent stimulator of vascular endothelial growth factor production, which may have implications for graft endothelialization and cardiovascular haemodynamics post-operatively. Copyright 2000 The European Society of Cardiology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032698     DOI: 10.1053/euhj.2000.2177

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  4 in total

1.  Study of molecular mechanism of Prostaglandin E1 in inhibiting coronary heart disease.

Authors:  H J Liu; J W Ma; Z Y Qiao; B Xu
Journal:  Mol Biol Rep       Date:  2013-10-22       Impact factor: 2.316

2.  Release of soluble vascular endothelial growth factor receptor-1 (sFlt-1) during coronary artery bypass surgery.

Authors:  Yves Denizot; Alexandre Leguyader; Elisabeth Cornu; Marc Laskar; Isabelle Orsel; Christelle Vincent; Nathalie Nathan
Journal:  J Cardiothorac Surg       Date:  2007-09-21       Impact factor: 1.637

3.  Alterations in plasma soluble vascular endothelial growth factor receptor-1 (sFlt-1) concentrations during coronary artery bypass graft surgery: relationships with post-operative complications.

Authors:  Yves Denizot; Alexandre Leguyader; Elisabeth Cornu; Marc Laskar; Isabelle Orsel; Christelle Vincent; Nathalie Nathan
Journal:  J Cardiothorac Surg       Date:  2008-04-18       Impact factor: 1.637

4.  Growth factors serum levels in coronary artery disease patients scheduled for bypass surgery: perioperative dynamics and comparisons with healthy volunteers.

Authors:  Inga Karu; Joel Starkopf; Kersti Zilmer; Mihkel Zilmer
Journal:  Biomed Res Int       Date:  2013-07-29       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.